Status:
TERMINATED
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
Lead Sponsor:
Hoosier Cancer Research Network
Collaborating Sponsors:
United States Department of Defense
Indiana University School of Medicine
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Detailed Description
OUTLINE: This is a multi-center study. Sample Collection: * Tumor sample * Serum sample Treatment Regimen: * All registered patients must be planning treatment with lonafarnib
Eligibility Criteria
Inclusion
- Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
- Age \> 18 years.
- Planned treatment with lonafarnib for metastatic breast cancer.
- Must consent to have a biopsy performed to obtain fresh tissue or be able to identify a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be obtained to complete the testing for this study.
Exclusion
- Planned treatment with any other treatment regimen
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01232881
Start Date
August 1 2009
End Date
November 1 2010
Last Update
April 28 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202